Status:
WITHDRAWN
Biomarker for Krabbe Disease (BioKrabbe)
Lead Sponsor:
CENTOGENE GmbH Rostock
Conditions:
Krabbe Disease
Eligibility:
All Genders
1+ years
Brief Summary
Development of a new MS-based biomarker for the early and sensitive diagnosis of Krabbe Disease from blood
Detailed Description
Krabbe disease is a rare, hereditary degenerative disorder of the central and peripheral nervous systems. It is characterized by the presence of globoid cells (cells that have more than one nucleus), ...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Informed consent will be obtained from the patient or the parents before any study related procedures.
- Patients of both gender from one year old
- The patient has a diagnosis of Krabbe Disease
- EXCLUSION CRITERIA:
- No Informed consent from the patient or the parents before any study related procedures.
- Patients younger than one year
- The patient has no diagnosis of Krabbe Disease
Exclusion
Key Trial Info
Start Date :
August 20 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01425489
Start Date
August 20 2018
End Date
February 28 2021
Last Update
February 13 2023
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital, Faculty of Medicine, Ain Shams University
Cairo, Egypt, 55131
2
Centogene AG
Rostock, Germany, 18055
3
Amrita Institute of Medical Sciences
Kerala, India, 682041
4
Navi Mumbai Institute of Research In Mental And Neurological Handicap (NIRMAN)
Mumbai, India, 400705